Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer

SEATTLE, April 21 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN ) today announced that the Company has enrolled the first patient in a Phase 1 clinical trial of D3263 in patients with advanced cancer. D3263 is Dendreon's lead small molecule drug candidate designed to target TRPM8...

Raptor Pharmaceuticals Provides Update on Targeting Platforms

Enters Collaboration on Receptor Associated Protein (RAP) Supports NeuroTrans(TM) Platform with Japanese Patent NOVATO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced updates on its preclinical p...

Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors

PRINCETON, N.J., Nov. 5 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) today announced that it has received a milestone payment of an undisclosed amount from its licensing partner, Centocor R&D Inc., for the completion of a Phase 2 trial of CNTO 95, a fully human antibody targeting t...

MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13

GAITHERSBURG, Md., April 15 /PRNewswire/ -- MedImmune today announced that it has advanced its efforts to develop CAT-354, a potential treatment for patients with asthma, with the start of two new trials with a monoclonal antibody (MAb) targeting interleukin-13 (IL-13). One of the studies is a...

Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies

-Combination of a Bavituximab Equivalent and an Agent that Re-Activates the Tumor Suppressor P53 Inhibited Tumor Growth Synergistically in Preclinical Breast Cancer Models- SAN DIEGO and TUSTIN, Calif., April 14 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (...

Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease

EINDHOVEN, the Netherlands, April 1 /PRNewswire/ -- The Center for Translational Molecular Medicine (CTMM) - a Dutch public-private partnership committed to the research and development of new techniques for the diagnosis and treatment of major diseases - announced today that nine projects wil...

Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma

- Study to Assess MEDI-528 in Stable Asthma and Exercise-Induced Bronchoconstriction - PLYMOUTH MEETING, Pa., March 18 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today reported that development partner, MedImmune, has initiated its fourth phase 2...

MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma

- Company Initiates Phase 2a Trial in Patients with Stable Asthma and Exercise-Induced Bronchoconstriction - GAITHERSBURG, Md., March 18 /PRNewswire/ -- MedImmune today announced that its clinical program studying an investigational treatment targeting interleukin-9 (IL-9) has...

MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis

GAITHERSBURG, Md., Nov. 26 /PRNewswire/ -- MedImmune, Inc. today announced that dosing of patients has begun in the first Phase 1 clinical trial of CAM- 3001, a fully human monoclonal antibody (MAb) targeting the alpha subunit of the granulocyte-macrophage colony stimulating factor receptor (G...

Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes

*Isis Now Has Two Drugs From Its Metabolic Disease Program In Clinical Development CARLSBAD, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today it has initiated a Phase 1 study of ISIS 325568, an antisense drug de...

Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA

GAITHERSBURG, Md. and CARLSBAD, Calif., April 18, 2007 /PRNewswire-FirstCall/ -- Micromet, Inc. and MedImmune, Inc. today announced data from a preclinical study in which BiTE(R) molecules targeting carcinoembryonal antigen (CEA) were shown to prevent subcutaneous tumor growth and formation of lun...

Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, announced results from two pre-clinical studies that support the role of SPARC (secreted protein acidic and rich in cysteine) expression in cancer and Abraxis' nanop...

Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology

FREISING-WEIHENSTEPHAN, Germany, June 21, 2007 /PRNewswire/ -- Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, announced today that its proprietary Duocalin(R) technology has successfully demonstrated dual targeting potential....

Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture

...rather than effectively addressed it," said Dr. David Leffell, M.D.; professor of dermatology and surgery at Yale University's School of Medicine. "By targeting skin directly where damage occurs (within the surface layer), NutriumMoisture technology helps build a foundation for the stratum corneum to become st...

FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent

...ill combination of the only approved drug, Tekturna, that works by directly targeting renin and decreasing the activity of the renin angiotensin aldosterone syst...Tekturna, a direct renin inhibitor, is the only drug that works by directly targeting renin and decreasing the activity of the RAAS. Renin is an enzyme produced ...

BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza

...South Korea. About BioCryst BioCryst is a biopharmaceutical company that has developed a diverse pipeline of novel therapeutics targeting major illnesses by employing crystallography and structure-based drug design. BioCryst is currently advancing investigational new drugs discovered in...

Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimer's Disease

...pporting our pioneering approach to treat or prevent Alzheimer's disease by targeting the proteins that cause the earliest stages of this disease". "As...is a leader in the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheim...

deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke

... and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 modulators with therapeutic applications in Alzhei...

Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer

... 70 references already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. As for leukemia, Ipsogen's goal is to provide diagnostic information that was not available until now. Ipsogen is also a partner of cho...

deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia

...logy of the disease and making it possible for us to begin to develop drugs targeting the underlying causes and not just the symptoms of the disease. One of the ...loped for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a...

Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia

...s to Editors: About Vantia Therapeutics Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets. Formed in 2008 as a spin-out of Ferring Research Ltd's small molecule R&D, it has two clinical phase products,...

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease

... selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has a strategic collaboration with Shir...

Alfacell Provides Shareholder Update

...r similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. For m...

Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells

... highly-potent drugs on extended and frequent dosing schedules and in combination with other drugs to maximize efficacy. The technology improves drug targeting and reduces the risk of side effects by combining drugs with ligands that are able to identify and attach to receptors found on tumor and other diseas...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

... preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. BiTE antibodies targeting CEA, MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. Forward-Looking Statements This release co...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

... preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. BiTE antibodies targeting CEA, MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. Forward-Looking Statements This release co...

Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines

...vandia, introduced on the market in 1999, is a member of the TZD class of oral anti-diabetic medications which improve blood sugar control by directly targeting insulin resistance, an underlying cause of type 2 diabetes. This helps the body respond better to its own natural insulin. Avandia is indicated as an ...

PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference

... ultimately results in the persistent inflammation underlying the disease. targeting the CCR9 chemokine receptor represents a novel approach for the treatment o...internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molec...

Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer

...ed therapy development in cancer, we are especially excited for our melanoma patients for whom there are few treatment options." PLX4032 works by targeting and destroying tumour cells carrying the BRAF mutation. BRAF is an important mediator of cell growth and division, but when mutated is known to cause ...

Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients

...he PI3K superfamily, including mTORC1/2, DNA-PK, PLK-1, CK2, ATM and PIM-1. SF1126 is designed to inhibit both angiogenesis and cell proliferation by targeting and binding to integrins that are expressed on the surface of new tumor vasculature and within the tumor compartment. In preclinical xenograft ...

Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506

...genic oral tyrosine kinase inhibitor (TKI) with a kinase inhibition profile targeting angiogenic, stromal and oncogenic receptor tyrosine kinases (TK). In precl...tion of tumor cell lines while promoting apoptosis (cell death) by directly targeting several oncogenic TK receptors. The clinical significance of these studies...

CuraGen to Present CR011-vcMMAE Data at ASCO

... The titles, dates, and times of the presentations are as follows: #9032 A phase I/II study of CR011-vcMMAE , an antibody-drug conjugate targeting glycoprotein NMB in patients with advanced melanoma. Sunday, May 31, 2009, poster presentation from 8:00 AM - 12:00 PM with a discussion session from ...

Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research

.... Mills, M.D., Ph.D., Chair, Department of Systems Biology, University of Texas M. D. Anderson Cancer Center; "An Integrated Approach to targeting Molecular Breast Cancer Molecular Subtypes and Their 'Resistance' Phenotypes " / Leaders: Joe W. Gray, Ph.D., Life Sciences Division Director, Lawr...

Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults

...le in Germany, the U.K., Greece, Austria, Denmark, Sweden, and Netherlands, with other European countries to follow. Vimpat(R) offers new way of targeting pathways involved in seizure onset Preclinical studies indicate that Vimpat(R) has a novel mechanism of action, although the precise mechanism by w...

Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting

...he PI3K superfamily, including mTORC1/2, DNA-PK, PLK-1, CK2, ATM and PIM-1. SF1126 is designed to inhibit both angiogenesis and cell proliferation by targeting and binding to specific integrins that are expressed on the surface of new tumor vasculature and within the tumor compartment. In preclinical xen...

Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma

...CRA) being studied for the treatment of several life-threatening diseases including RCC and NSCLC. Talactoferrin mediates its anti-cancer activity by targeting dendritic cells which play an important role in activating innate and adaptive immunity. After being transported into the gut associated lymphoid tis...

TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics

...bout Osmetech Osmetech is an international diagnostics business operating in Boston and Pasadena in the US to serve the molecular diagnostic market targeting hospitals and reference laboratories. Osmetech has a strong patent portfolio and markets FDA 510(k) cleared first- and second-generation electrochemi...

Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki

...sistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated US$17bn in 2008.[1] Novexel currently has two novel antibacterials in Phase...

Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009

.... Accessed on 5 May 2009. Ledermann, J. A. "A randomised Phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 followign treatment of relapsed ovarian cancer (OC)." Oral presentation, Clinical Science Symposium. Monday, 1 June 2009, Session Time...

Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis

...demonstration of efficacy from a well-designed and well-executed study," said Howard H. Pien, Chairman and CEO of Medarex. "These results show that by targeting the chemokine IP-10 with our MDX-1100 antibody, we may be able to offer a potentially important and novel treatment option for rheumatoid arthritis an...